Moffitt Cancer Center and Research Institute
Welcome,         Profile    Billing    Logout  
 18 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zager, Jonathan
FOCUS, NCT02678572: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Completed
3
102
Europe, US
Melphalan/HDS, Alkeran
Delcath Systems Inc., IQVIA Biotech
Melanoma, Ocular
05/23
08/23
NCT05022901: An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Active, not recruiting
3
30
US
Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS), percutaneous hepatic perfusion, PHP, HEPZATO
Delcath Systems Inc.
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
03/24
03/24
Neo-DREAM, NCT03567889: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

Recruiting
3
186
Europe, US
Daromun, Surgery, Adjuvant therapy
Philogen S.p.A.
Melanoma Stage IIIB/C
06/24
06/26
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
3
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
NCT04526730: Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Active, not recruiting
2
17
US
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System, Electroporation
H. Lee Moffitt Cancer Center and Research Institute, OncoSec Medical Incorporated
Melanoma
06/28
06/28
PV-10-MM-1201, NCT02557321: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Active, not recruiting
1/2
50
US
PV-10, Rose Bengal Disodium, Pembrolizumab
Provectus Biopharmaceuticals, Inc.
Melanoma
05/23
04/25
NCT04975152: Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
1
30
US
Cemiplimab-Rwlc, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Regeneron Pharmaceuticals, Sanofi-Synthelabo
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
07/24
07/26
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver

No Longer Available
N/A
US
Melphalan, Percutaneous Hepatic Perfusion
Delcath Systems Inc.
Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
 
 
Duval, Michel
NCT04018937: Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Recruiting
2
58
Canada, US
Alemtuzumab, Campath, Fludarabine, Fludara, Melphalan, Alkeran, Evomela
Emory University
Sickle Cell Disease
01/27
01/27
NCT03910660: A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Checkmark Initial interim data from trial in combination with BXCL701 for treatment-emergent neuroendocrine prostate cancer
Oct 2020 - Oct 2020: Initial interim data from trial in combination with BXCL701 for treatment-emergent neuroendocrine prostate cancer
Checkmark Data from P1b part of P1b/2 trial in combination with BXCL701 for Neuroendocrine prostate cancer
Apr 2020 - Apr 2020: Data from P1b part of P1b/2 trial in combination with BXCL701 for Neuroendocrine prostate cancer
Active, not recruiting
1b/2
98
Europe, US
BXCL701 plus Pembrolizumab, BXCL701 plus Pembro, BXCL701 monotherapy, BXCL701
BioXcel Therapeutics Inc
Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
10/23
12/25
Soliman, Hatem
SGNTUC-019, NCT04579380: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCT05115474: Study of Screening Brain MRIs in Stage IV Breast Cancer

Recruiting
2
100
US
Magnetic Resonance Imaging, MRI
H. Lee Moffitt Cancer Center and Research Institute, Florida Breast Cancer Foundation
Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer
08/24
08/24
NATASHA, NCT05325632: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting
2
53
US
HER-2 pulsed DC1, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Paclitaxel, Abraxane, Resection surgery
H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration
HER2-positive Breast Cancer
01/25
01/25
NCT02779855: Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Active, not recruiting
1/2
50
US
Talimogene laherparepvec, IMLYGIC™, modified herpes simplex 1 virus, Paclitaxel, Taxol®
H. Lee Moffitt Cancer Center and Research Institute, Amgen
Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
09/20
08/24
NCT04588545: Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Recruiting
1/2
39
US
Radiation Therapy, Pertuzumab, Trastuzumab
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
11/24
11/24
MCC-20899, NCT04923542: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Recruiting
1/2
31
US
Stereotactic Radiosurgery (SRS), Abemaciclib, Verzenio, Ramiven, Endocrine therapy, hormone therapy
H. Lee Moffitt Cancer Center and Research Institute, Eli Lilly and Company
Brain Metastases, HR+ Metastatic Breast Cancer
12/24
12/24
NCT06435351: Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Recruiting
1
16
US
Leukapheresis, Dendritic Cell (DC) Vaccine
H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Triple Negative Breast Cancer
05/29
05/29
NCT05694364: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Recruiting
1
88
US
Fludarabine, Fludara, Cyclophosphamide, PRGN-3007
H. Lee Moffitt Cancer Center and Research Institute, Precigen, Inc
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
01/26
01/26
NCT03387553: HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Active, not recruiting
1
31
US
Dendritic Cell Vaccine (DC1), Immunotherapy, Neoadjuvant Chemotherapy, TCHP, Curative Surgery
H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense
Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, Stage II Breast Cancer, Stage III Breast Cancer
08/26
08/26
Cohn, Allen
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Calendar Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
01/25
05/25
NET-202, NCT05997056: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Recruiting
2
21
US
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
05/25
12/25
ALPHAMEDIX02, NCT05153772: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Active, not recruiting
2
69
US
AlphaMedix, Pb212-octreotide analog
Radiomedix, Inc., Orano Med LLC
Neuroendocrine Tumors
10/26
10/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
144
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Recruiting
1
150
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
12/23
05/24
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
Jump, Helen M
No trials found
Arnone, Gina
No trials found
Turba, Elyce
No trials found
Borisenko, Lynn
No trials found
Miller, Natalie
No trials found

Download Options